Lecap Asset Management Ltd. Sells 22,196 Shares of DexCom, Inc. (NASDAQ:DXCM)

Lecap Asset Management Ltd. cut its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 46.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,347 shares of the medical device company’s stock after selling 22,196 shares during the period. Lecap Asset Management Ltd.’s holdings in DexCom were worth $1,971,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of DXCM. Sanctuary Advisors LLC bought a new stake in shares of DexCom in the 2nd quarter valued at approximately $1,395,000. Czech National Bank lifted its stake in shares of DexCom by 7.7% in the 3rd quarter. Czech National Bank now owns 81,632 shares of the medical device company’s stock valued at $5,473,000 after purchasing an additional 5,850 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of DexCom by 69.5% in the 3rd quarter. GAMMA Investing LLC now owns 5,593 shares of the medical device company’s stock valued at $375,000 after purchasing an additional 2,293 shares during the last quarter. Dynamic Advisor Solutions LLC lifted its stake in shares of DexCom by 14.6% in the 3rd quarter. Dynamic Advisor Solutions LLC now owns 3,077 shares of the medical device company’s stock valued at $206,000 after purchasing an additional 391 shares during the last quarter. Finally, Atomi Financial Group Inc. bought a new stake in shares of DexCom in the 3rd quarter valued at approximately $264,000. 97.75% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,342 shares of company stock worth $3,628,069. 0.30% of the stock is currently owned by company insiders.

DexCom Trading Down 0.5 %

Shares of NASDAQ:DXCM opened at $88.32 on Friday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The business’s fifty day simple moving average is $81.35 and its 200-day simple moving average is $75.69. The company has a market capitalization of $34.50 billion, a PE ratio of 52.89, a P/E/G ratio of 2.23 and a beta of 1.14. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Analyst Upgrades and Downgrades

DXCM has been the subject of several analyst reports. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Oppenheimer decreased their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Sanford C. Bernstein raised their price target on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Leerink Partners decreased their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, Raymond James decreased their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $98.41.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.